Advertisement

Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results

  • Yoshihiko Manabe
  • Yuta Shibamoto
  • Fumiya Baba
  • Takeshi Yanagi
  • Hiromitsu Iwata
  • Akifumi Miyakawa
  • Taro Murai
  • Katsuhiro Okuda
Original Article
  • 13 Downloads

Abstract

Purpose

The optimal treatment for hilar or mediastinal lymph node (LN) recurrence developing after stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer remains unclear. This study evaluated 5-year results of radiotherapy in such patients in comparison with those for postoperative LN metastases.

Materials and methods

Between 2004 and 2013, 27 patients with hilar and/or mediastinal LN metastases without local recurrence and distant metastasis after SBRT (n = 14) or surgery (n = 13) were treated with definitive conventional radiotherapy. The median total dose for treating metastatic LN was 60 Gy for the post-SBRT group and 66 Gy for the post-surgery group.

Results

The median follow-up for the 5 surviving patients was 62 months. The overall survival, cause-specific survival, progression-free survival, and local control rates at 5 years after mediastinal irradiation were 14%, 45%, 21%, and 58%, respectively, for the 14 patients in the post-SBRT group. These rates were 36%, 45%, 39%, and 92%, respectively for the post-surgery group (p = 0.066, 0.64, 0.38, and 0.41, respectively). Four patients in the post-SBRT group survived 3 or more years (range 36–92 months) after mediastinal irradiation.

Conclusions

A proportion of patients in both groups achieved long-term survival by conventional radiotherapy.

Keywords

Non-small cell lung cancer Stereotactic body radiotherapy Lymph node metastasis Re-irradiation Salvage radiotherapy 

Notes

Acknowledgements

A part of this work was presented at the ASTRO’s 59th Annual Meeting, San Diego, September 24–27, 2017. We thank all staffs of the radiation oncology section.

Compliance with ethical standards

Conflicts of interest

None declared.

Ethical standards

All procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments.

References

  1. 1.
    Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630–7.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Iwata H, Demizu Y, Fujii O, Terashima K, Mima M, Niwa Y, et al. Long-term outcome of proton therapy and carbon-ion therapy for large (T2a–T2bN0M0) non-small-cell lung cancer. J Thorac Oncol. 2013;8:726–35.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93:989–96.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Shibamoto Y, Hashizume C, Baba F, Ayakawa S, Miyakawa A, Murai T, et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. J Thorac Oncol. 2015;10:960–4.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Wink KCJ, van Baardwijk A, Troost EGC, De Ruysscher D.  Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: incidence and proposed risk factors. Cancer Treat Rev. 2017;56:8–15.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Manabe Y, Shibamoto Y, Baba F, Murata R, Yanagi T, Hashizume C, et al. Radiotherapy for hilar or mediastinal lymph node metastases after definitive treatment with stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer. Pract Radiat Oncol. 2012;2:e137–43.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Hayashi K, Yamamoto N, Karube M, Nakajima M, Tsuji H, Ogawa K, et al. Feasibility of carbon-ion radiotherapy for re-irradiation of locoregionally recurrent, metastatic, or secondary lung tumors. Cancer Sci. 2018;109:1562–9.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    McAvoy SA, Ciura KT, Rineer JM, Allen PK, Liao Z, Chang JY, et al. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol. 2013;109:38–44.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Ward MC, Oh SC, Pham YD, Woody NM, Marwaha G, Videtic GM, et al. Isolated nodal failure after stereotactic body radiotherapy for lung cancer: the role for Salvage mediastinal radiotherapy. J Thorac Oncol. 2016;11:1558–64.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Baba F, Shibamoto Y, Tomita N, Ikeya-Hashizume C, Oda K, Ayakawa S, et al. Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results. Radiat Oncol. 2009;4:15.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Rulach R, Hanna GG, Franks K, McAleese J, Harrow S. Re-irradiation for locally recurrent lung cancer: evidence, risks and benefits. Clin Oncol (R Coll Radiol). 2018;30:101–09.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II–III inoperable non-small cell lung cancer. Radiother Oncol. 2015;115:367–72.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Ono T, Nakamura T, Yamaguchi H, Azami Y, Takayama K, Suzuki M, et al. Clinical results of proton beam therapy for elderly patients with non-small cell lung cancer. Radiat Oncol. 2018;13:19.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Okami J, Nishiyama K, Fujiwara A, Konishi K, Kanou T, Tokunaga T, et al. Radiotherapy for postoperative thoracic lymph node recurrence of non-small-cell lung cancer provides better outcomes if the disease is asymptomatic and a single-station involvement. J Thorac Oncol. 2013;8:1417–24.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Kim E, Song C, Kim MY, Kim JS. Long-term outcomes after salvage radiotherapy for postoperative locoregionally recurrent non-small-cell lung cancer. Radiat Oncol J. 2017;35:55–64.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Seol KH, Lee JE, Cho JY, Lee DH, Seok Y, Kang MK. Salvage radiotherapy for regional lymph node oligo-recurrence after radical surgery of non-small cell lung cancer. Thorac Cancer. 2017;8:620–29.CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Goto K, Endo M, Kusumoto M, Yamamoto N, Ohe Y, Shimizu A, et al. Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis. Cancer Sci. 2016;107:1837–42.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Pollom EL, Deng L, Pai RK, Brown JM, Giaccia A, Loo BW Jr, et al. Gastrointestinal toxicities with combined antiangiogenic and stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92:568–76.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Japan Radiological Society 2018

Authors and Affiliations

  1. 1.Department of RadiologyNagoya City University Graduate School of Medical SciencesNagoyaJapan
  2. 2.Department of RadiotherapyNagoya City West Medical CenterNagoyaJapan
  3. 3.Department of Radiation Oncology, Nagoya Proton Therapy CenterNagoya City West Medical CenterNagoyaJapan
  4. 4.Department of Oncology, Immunology and SurgeryNagoya City University Graduate School of Medical SciencesNagoyaJapan

Personalised recommendations